about
Clinical pharmacology of midazolam in neonates and children: effect of disease-a reviewMaternal urinary bisphenol a during pregnancy and maternal and neonatal thyroid function in the CHAMACOS studyThe effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Liver zonation: Novel aspects of its regulation and its impact on homeostasis.Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.Children's susceptibility to chemicals: a review by developmental stage.Cell-based models to study hepatic drug metabolism and enzyme induction in humans.The fate and effects of xenobiotics in human placenta.Developmental pharmacology: neonates are not just small adults...Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.Weight-of-evidence evaluation of reproductive and developmental effects of low doses of bisphenol A.Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals.Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues.Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.Specific features of pharmacokinetics in children.Technological challenges of addressing new and more complex migrating products from novel food packaging materials.Interactive effects between CYP1A1 genotypes and environmental polychlorinated dibenzo-p-dioxins and dibenzofurans exposures on liver function profile.Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Göttingen minipig: an immunohistochemical evaluation.Changes of multiple biotransformation phase I and phase II enzyme activities in human fetal adrenals during fetal development.Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.Direct dosing of preweaning rodents in toxicity testing and research: deliberations of an ILSI RSI Expert Working Group.Metabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes.Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A
P2860
Q27006333-8A2DB3B3-35F0-4B36-9C41-175837A026B3Q28393523-67E43FEE-1DD8-441C-B499-FF8E99FDD831Q30490602-2AC653E8-6BC4-4162-8E22-99F821D9A84DQ33886995-58A1060E-C774-4A2E-9505-63124123B07DQ34626408-54EB59DA-621B-4C81-8FB4-CE0AE089103BQ35039302-345A4358-3A70-4384-B26B-4F68FEFCB9AFQ35826421-DB1176FE-9F8A-438B-9577-BA740DA21AC0Q35977793-F4F02885-B849-49AB-8400-ABB6AB3E0356Q36572634-65331266-A52E-4050-8858-73562EC2A2E3Q36835803-DD4A6462-8232-4339-9A29-9A8F7A08450AQ37127683-67172F4A-4360-4820-83A7-553F6FDE6AF1Q37272782-15F302D5-903A-453D-92DC-628FD3DC9C4EQ37299378-FFA5426F-D1FC-4C2D-9A4F-69D0AFE5A57EQ37409080-63AA0A32-6BF0-4766-99C0-4D49D7DD26AAQ37604379-C5A5A7C5-BDA4-47CB-B023-ECCF71F1DBEAQ37659046-B1B761E5-7A0C-459D-AB1B-445042755BC1Q38717340-808DCF5B-24A1-4179-BCC8-E35BC283FC94Q39926132-EE340764-0382-4166-825D-03DE67343467Q43330909-EA491272-2B4B-4677-8C2B-511C0F52513CQ45400881-24879733-0164-4A9B-B00C-9BB303281C61Q46794510-1FE8D33D-591E-4272-A778-893D6D7FCACBQ51732246-BECCFBE2-5C24-43DB-A374-3EF32893D159Q53270128-B4CF3929-924B-4524-AC20-394F1ED84202Q55384558-B80AD7A7-D080-4C67-8DF4-CAB31AD8208AQ58392333-6D383993-CBE3-4751-BC79-E954C1A679D2
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Fetal hepatic drug elimination.
@ast
Fetal hepatic drug elimination.
@en
type
label
Fetal hepatic drug elimination.
@ast
Fetal hepatic drug elimination.
@en
prefLabel
Fetal hepatic drug elimination.
@ast
Fetal hepatic drug elimination.
@en
P2093
P1476
Fetal hepatic drug elimination.
@en
P2093
P304
P356
10.1016/S0163-7258(99)00046-7
P577
1999-12-01T00:00:00Z